Linda Llewelyn Sells 6,442 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the sale, the insider now directly owns 92,260 shares of the company’s stock, valued at $535,108. The trade was a 6.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Linda Llewelyn also recently made the following trade(s):

• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96.

Health Catalyst Price Performance

HCAT opened at $5.49 on Friday. The firm has a market cap of $334.06 million, a PE ratio of -4.07 and a beta of 1.36. The stock has a 50-day moving average price of $7.61 and a 200-day moving average price of $7.52. Health Catalyst, Inc. has a 1 year low of $5.35 and a 1 year high of $10.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the firm posted ($0.22) earnings per share. Sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth $34,000. Quarry LP lifted its holdings in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at $59,000. Mackenzie Financial Corp bought a new stake in Health Catalyst in the 2nd quarter worth about $70,000. Finally, Quadrature Capital Ltd bought a new stake in Health Catalyst in the 3rd quarter worth about $84,000. 85.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HCAT. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Citigroup dropped their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.